Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Francis Giles, M.D., Susan O’Brien, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2554.

https://doi.org/10.1182/blood.V110.11.2554.2554

Published: 2007

Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.

Blood (2007) 110 (11): 1851.

https://doi.org/10.1182/blood.V110.11.1851.1851

Published: 2007

Journal Articles

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Marie Ann Richie, Gautam Borthakur, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2007) 110 (11): 3542.

https://doi.org/10.1182/blood.V110.11.3542.3542

Published: 2007

Journal Articles

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Alfonso Quintás-Cardama, MD, Ayalew Tefferi, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Stefan Faderl, M.D., Guillermo Garcia-Manero, M.D., Gautam Borthakur, M.D., Neda Bell, M.D., Catriona Byrne, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D

Blood (2007) 110 (11): 3545.

https://doi.org/10.1182/blood.V110.11.3545.3545

Published: 2007

Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.

Blood (2006) 108 (11): 2612.

https://doi.org/10.1182/blood.V108.11.2612.2612

Published: 2006

Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.

Blood (2006) 108 (11): 2652.

https://doi.org/10.1182/blood.V108.11.2652.2652

Published: 2006

Journal Articles

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

Constantine S. Tam, MD, Francis Giles, M.D., Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2705.

https://doi.org/10.1182/blood.V108.11.2705.2705

Published: 2006

Journal Articles

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., STeven Kornblau, M.D., Elihu Estey, M.D., Marilyn Nemri, R.N., Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2706.

https://doi.org/10.1182/blood.V108.11.2706.2706

Published: 2006

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

Journal Articles

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Taghi Manshouri, PhD, Zeev Estrov, M.D., Alfonso Quintas-Cardama, M.D., Jorge Cortes, M.D., Francis Giles, M.D., David Harris, MS, Waldemar Priebe, PhD;MS, Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD.

Blood (2006) 108 (11): 4885.

https://doi.org/10.1182/blood.V108.11.4885.4885

Published: 2006

Journal Articles

Effect of Tyrosine Kinase Inhibitor INNO-406 on Human Mast Cells Bearing Mutated c-KIT Tyrosine Kinase.

Jingxuan Pan, MD, PhD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 4890.

https://doi.org/10.1182/blood.V108.11.4890.4890

Published: 2006

Journal Articles

Interferon Therapy Is Predictive Factor for Improved Survival in Patients with Essential Thrombocythemia (ET).

Elias Jabbour, MD, Antoine Harb, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Sherry Pierce, BSN.BA, Jianqin Shan, Zeev Estrov, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4897.

https://doi.org/10.1182/blood.V108.11.4897.4897

Published: 2006

Journal Articles

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Alfonso Quintas-Cardama, MD, Ayalew Tefferi, M.D., Jorge Cortes, M.D., Animesh Pardanani, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Pat Ault, R.N., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4902.

https://doi.org/10.1182/blood.V108.11.4902.4902

Published: 2006

Journal Articles

A Phase II Study of Oral Interferon-Alpha (IFN-a) for Patients with Essential Thrombocythemia or Polycythemia Vera.

Alfonso Quintas-Cardama, MD, Francis Giles, M.D., Jorge Cortes, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4880.

https://doi.org/10.1182/blood.V108.11.4880.4880

Published: 2006

Journal Articles

Denileukin Diftitox (Ontak™) Therapy for Patients with Systemic Mastocytosis.

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4881.

https://doi.org/10.1182/blood.V108.11.4881.4881

Published: 2006

Journal Articles

The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.

Jingpan Pan, MD, PhD, Alfonso Quintas-Cardama, M.D., Hagop Kantarjian, M.D., Peter Lamb, Ayalew Tefferi, Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4882.

https://doi.org/10.1182/blood.V108.11.4882.4882

Published: 2006

Journal Articles

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Mary Ann Richie, R.N., Gautam Borthakur, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4884.

https://doi.org/10.1182/blood.V108.11.4884.4884

Published: 2006

Journal Articles

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

Gerald S. Falchook, MD, Richard Champlin, M.D., F.B. Hagemeister, M.D., Chitra Hosing, M.D., Larry W. Kwak, M.D., Susan O’Brien, M.D, Maria Alma Rodriguez, M.D., Srdan Verstovsek, M.D., Barbara Pro, M.D.

Blood (2006) 108 (11): 2460.

https://doi.org/10.1182/blood.V108.11.2460.2460

Published: 2006

Journal Articles

Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).

Yasuhiro Oki, MD, Hagop M. Kantarjian, MD, Susan O’Brien, MD, Srdan Verstovsek, M.D, Ph.D, Vazaganush Gharibyan, Jorge Cortes, MD, Gail M. Morris, Guillermo Garcia-Manero, MD, Jean-Pierre Issa, MD

Blood (2005) 106 (11): 1099.

https://doi.org/10.1182/blood.V106.11.1099.1099

Published: 2005

Journal Articles

Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.

Joya Chandra, Ph.D., Jeannette Tracy, Mercedes Gorre, Ph.D., Moshe Talpaz, M.D., James Griffin, M.D., Srdan Verstovsek, M.D., Ph.D., Miloslav Beran, M.D., Charles Sawyers, M.D., Edward Sausville, M.D., Scott Kaufmann, M.D., Ph.D.

Blood (2004) 104 (11): 2097.

https://doi.org/10.1182/blood.V104.11.2097.2097

Published: 2004

NARROW

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Effect of Tyrosine Kinase Inhibitor INNO-406 on Human Mast Cells Bearing Mutated c-KIT Tyrosine Kinase.

Interferon Therapy Is Predictive Factor for Improved Survival in Patients with Essential Thrombocythemia (ET).

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

A Phase II Study of Oral Interferon-Alpha (IFN-a) for Patients with Essential Thrombocythemia or Polycythemia Vera.

Denileukin Diftitox (Ontak™) Therapy for Patients with Systemic Mastocytosis.

The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).

Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only